Abstract 4663: BGB-21447, a next-generation Bcl-2 inhibitor, demonstrates superior potency and overcomes Venetoclax resistance in preclinical models of hematologic malignancies
Year: 2026
Type: conference-abstract
Source: Cancer Research
Institution: BeOne Medicines (Switzerland)
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7148868911
Cites:
Cited by:
Related to: